- Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics Business Wire
- Bristol Myers to buy startup Orbital Therapeutics, building out cell therapy pipeline statnews.com
- BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence Fierce Biotech
- BMS Makes $1.5B Cell Therapy Play With Orbital Takeover BioSpace
- Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition Endpoints News
Source link
